In addition to outlining five ways to optimize your message strategy and drive sales, this toolkit also includes real messages and payer reactions in rheumatoid arthritis.
Learn how a P&T review helped one pharma company understand how its product would be assessed, leading to a new focus on gathering real-world evidence.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.
This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.
Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.
MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).
Description
